1,721,013 research outputs found
Parthenolide: From plant shoots to cancer roots
No full textParthenolide (PTL), a sesquiterpene lactone (SL) originally purified from the shoots of feverfew (Tanacetum parthenium), has shown potent anticancer and anti-inflammatory activities. It is currently being tested in cancer clinical trials. Structure-activity relationship (SAR) studies of parthenolide revealed key chemical properties required for biological activities and epigenetic mechanisms, and led to the derivatization of an orally bioavailable analog, dimethylamino-parthenolide (DMAPT). Parthenolide is the first small molecule found to be selective against cancer stem cells (CSC), which it achieves by targeting specific signaling pathways and killing cancer from its roots. In this review, we highlight the exciting journey of parthenolide, from plant shoots to cancer roots. © 2013 Elsevier Ltd. All rights reserved.AWANG DVC, 1991, J NAT PROD, V54, P1516, DOI 10.1021-np50078a005; Birnie R, 2008, GENOME BIOL, V9, DOI 10.1186-gb-2008-9-5-r83; BOHLMANN F, 1982, PHYTOCHEMISTRY, V21, P2543, DOI 10.1016-0031-9422(82)85253-9; Bork PM, 1997, FEBS LETT, V402, P85, DOI 10.1016-S0014-5793(96)01502-5; Cheng D., 2005, AACR M, V1, P988; Crooks P.A., 2012, Patent number, Patent No. [US 7312242, 7312242]; Czyz M, 2013, CANCER BIOL THER, V14, P135, DOI 10.4161-cbt.22952; Dell'Agli M, 2009, BIOORG MED CHEM LETT, V19, P1858, DOI 10.1016-j.bmcl.2009.02.080; Dey A, 2008, NAT REV DRUG DISCOV, V7, P1031, DOI 10.1038-nrd2759; Diamanti P, 2013, BLOOD, V121, P1384, DOI 10.1182-blood-2012-08-448852; Dreesen O, 2007, STEM CELL REV, V3, P7, DOI 10.1007-s12015-007-0004-8; Fonrose X, 2007, CANCER RES, V67, P3371, DOI 10.1158-0008-5472.CAN-06-3732; Gao ZW, 2010, CURR CANCER DRUG TAR, V10, P705; Garcia-Pineres AJ, 2001, J BIOL CHEM, V276, P39713, DOI 10.1074-jbc.M101985200; Ghantous A, 2010, DRUG DISCOV TODAY, V15, P668, DOI 10.1016-j.drudis.2010.06.002; Ghantous A, 2012, CANCER PREV RES, V5, P1298, DOI 10.1158-1940-6207.CAPR-12-0230; Gopal YV, 2007, CHEM BIOL, V14, P813, DOI 10.1016-j.chembiol.2007.007; Gunn EJ, 2011, LEUKEMIA LYMPHOMA, V52, P1085, DOI 10.3109-10428194.2011.555891; Guzman ML, 2005, EXPERT OPIN BIOL TH, V5, P1147, DOI 10.1517-14712598.5.9.1147; Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182-blood-2004-10-4135; Guzman ML, 2007, BLOOD, V110, P4427, DOI 10.1182-blood-2007-05-090621; Hassane DC, 2010, BLOOD, V116, P5983, DOI 10.1182-blood-2010-04-278044; Hassane DC, 2008, BLOOD, V111, P5654, DOI 10.1182-blood-2007-11-126003; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hobbs C., 1989, HERBAL GRAM, V20, P267; Idris AI, 2009, MOL CANCER THER, V8, P2339, DOI 10.1158-1535-7163.MCT-09-0133; Ivanenkov YA, 2011, MINI-REV MED CHEM, V11, P55; Kawasaki BT, 2009, PROSTATE, V69, P827, DOI 10.1002-pros.20931; Kim IH, 2012, EXP MOL MED, V44, P448, DOI 10.3858-emm.2012.44.7.051; Kim S.L., 2013, CANC LETT, V41, P1547; Kim S.L., 2012, INT J ONCOL, DOI DOI 10.3892-IJ0.2012.1587; Kim YR, 2010, J PHARMACOL EXP THER, V335, P389, DOI 10.1124-jpet.110.169367; Kishida Y, 2007, CLIN CANCER RES, V13, P59, DOI 10.1158-1078-0432.CCR-06-1559; KNIGHT DW, 1995, NAT PROD REP, V12, P271, DOI 10.1039-np9951200271; Kreuger MRO, 2012, ANTI-CANCER DRUG, V23, P883, DOI 10.1097-CAD.0b013e328356cad9; Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016-S1074-5521(01)00049-7; Lesiak K, 2010, MELANOMA RES, V20, P21, DOI 10.1097-CMR.0b013e328333bbe4; Liu Y, 2008, J CONTROL RELEASE, V129, P18, DOI 10.1016-j.jconrel.2008.03.022; Liu ZF, 2009, J PHARMACOL EXP THER, V329, P505, DOI 10.1124-jpet.108.147934; Mathema VB, 2012, INFLAMMATION, V35, P560, DOI 10.1007-s10753-011-9346-0; Merfort I, 2011, CURR DRUG TARGETS, V12, P1560; Nakabayashi H, 2012, BMC CANCER, V12, DOI 10.1186-1471-2407-12-453; Nakshatri H., 2005, Patent, Patent No. [US 6890946 B2, 6890946]; Nasim S, 2011, BIOORGAN MED CHEM, V19, P1515, DOI 10.1016-j.bmc.2010.12.045; Nasim S, 2008, BIOORG MED CHEM LETT, V18, P3870, DOI 10.1016-j.bmcl.2008.06.050; Neelakantan S, 2009, BIOORG MED CHEM LETT, V19, P4346, DOI 10.1016-j.bmcl.2009.05.092; Oka D, 2007, INT J CANCER, V120, P2576, DOI 10.1002-ijc.22570; Zhang Siyuan, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P239, DOI 10.2174-1568011053765976; Pajak B, 2008, FOLIA HISTOCHEM CYTO, V46, P129, DOI 10.2478-v10042-008-0019-2; Pareek Anil, 2011, Pharmacogn Rev, V5, P103, DOI 10.4103-0973-7847.79105; Peese K., 2010, DRUG DISCOV TODAY, V15, P253; Pei SS, 2012, BEST PRACT RES CL HA, V25, P415, DOI 10.1016-j.beha.2012.10.003; Salisbury CM, 2008, J AM CHEM SOC, V130, P2184, DOI 10.1021-ja074138u; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038-nature06489; Schneider-Stock R, 2012, FRONT BIOSCI-LANDMRK, V17, P129, DOI 10.2741-3919; Shanmugam R, 2011, INT J CANCER, V128, P2481, DOI 10.1002-ijc.25587; Shanmugam R, 2010, PROSTATE, V70, P1074, DOI 10.1002-pros.21141; Shanmugam R, 2006, PROSTATE, V66, P1498, DOI 10.1002-pros.20482; Shi XK, 2012, ANTIOXID REDOX SIGN, V16, P1215, DOI 10.1089-ars.2012.4529; Siedle B, 2004, J MED CHEM, V47, P6042, DOI 10.1021-jm049937r; Skalska J, 2009, PLOS ONE, V4, DOI 10.1371-journal.pone.0008115; Sohma I, 2011, CANCER GENOM PROTEOM, V8, P39; Spagnuolo P.A., 2013, LEUKEMIA, DOI DOI 10.1038-1EU.2013.9; Stojakowska A, 1997, PLANT CELL TISS ORG, V47, P159, DOI 10.1023-A:1005930209494; Sweeney CJ, 2005, MOL CANCER THER, V4, P1004, DOI 10.1158-1535-7163.MCT-05-0030; Taguchi T, 2006, J ENDOCRINOL, V188, P321, DOI 10.1677-joe.1.06418; Tanaka K, 2005, J PHARMACOL EXP THER, V315, P624, DOI 10.1124-jpet.105.088674; Uchibori R, 2013, CANCER RES, V73, P364, DOI 10.1158-0008-5472.CAN-12-0088; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038-nrc3368; Vegeler Reid C, 2007, J Surg Res, V143, P169, DOI 10.1016-j.jss.2007.08.007; Wang CM, 2012, J BIOCHEM MOL TOXIC, V26, P35, DOI 10.1002-jbt.20411; Wang W, 2009, PANCREAS, V38, pE114, DOI 10.1097-MPA.0b013e3181a0b6f2; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038-ng1941; WIEDHOPF RM, 1973, J PHARM SCI, V62, P345, DOI 10.1002-jps.2600620244; Won YK, 2004, CARCINOGENESIS, V25, P1449, DOI 10.1093-carcin-bgh151; Yi Juan, 2010, Zhongguo Zhong Yao Za Zhi, V35, P219; Yip-Schneider MT, 2008, PANCREAS, V37, pE45, DOI 10.1097-MPA.0b013e318172b4dd; Yip-Schneider MT, 2007, MOL CANCER THER, V6, P1736, DOI 10.1158-1535-7163.MCT-06-0794; Zhang DL, 2009, MOL CANCER RES, V7, P1139, DOI 10.1158-1541-7786.MCR-08-0410; Zhou JB, 2008, CELL CYCLE, V7, P1360, DOI 10.4161-cc.7.10.5953; Zhou JB, 2008, BREAST CANCER RES TR, V111, P419, DOI 10.1007-s10549-007-9798-y; Zobalova R., 2011, CANC STEM CELLS THEO, P361; Zuch D, 2012, J CELL BIOCHEM, V113, P1282, DOI 10.1002-jcb.240028141
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Full text linkWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
koamabayili/VECTRON-author-checklist: VECTRON author checklist
No full textWe have done our best to complete the author checklist relating to the use of animals in the hut study. Note that the objective for the hut study was to evaluate the IRS treatment applications for residual efficacy against Anopheles mosquitoes, including the local An. coluzzii mosquito population. Cows were only used to attract mosquitoes into the huts and no tests were carried out directly on the cows. The author checklist is intended for use with studies where experiments are carried out on animals, which is why we have had such difficulty in completing this for the hut study, as many of the questions do not relate to how the cows were used
Author-wise bibliometric analysis based on entropy.
No full textAuthor-wise bibliometric analysis based on entropy.</p
Author Under Sail The Imagination of Jack London, 1893-1902
No full textIn Author Under Sail, Jay Williams offers the first complete literary biography of Jack London as a professional writer engaged in the labor of writing. It examines the authorial imagination in London's work, the use of imagination in both his fiction and nonfiction, and the ways he defined imagination in the creative process in his business dealings with his publishers, editors, and agents. In this first volume of a two-volume biography, Williams traverses the years 1893 to 1902, from London's "Story of a Typhoon" to The People of the Abyss. The Jack London who emerges in the pages of Author Under Sail is a writer whose partnership with publishers, most notably his productive alliance with George Brett of Macmillan, was one of the most formative in American literary history. London pioneered many author models during the heyday of realism and naturalism, blurring the boundaries of these popular genres by focusing on absorption and theatricality and the representation of the seen and unseen. London created an impassioned, sincere, and extremely personal realism unlike that of other American writers of the time. Author Under Sail is a literary tour de force that reveals the full range of London as writer, creative citizen, and entrepreneur at the same time it sheds light on the maverick side of machine-age literature.Intro -- Title Page -- Copyright Page -- Dedication -- Contents -- Acknowledgments -- Introduction -- 1. Spirit Truth -- 2. From Absorption to Theatricality and Back Again -- 3. "I Will Build a New Present" -- 4. Sons as Authors -- 5. Fathers as Publishers -- 6. The Daughter as Author -- 7. Lovers as Authors -- 8. At Sea with the Family -- 9. Yellow News, Yellow Stories -- 10. The Return Home -- Notes -- Bibliography -- Index -- About Jay WilliamsIn Author Under Sail, Jay Williams offers the first complete literary biography of Jack London as a professional writer engaged in the labor of writing. It examines the authorial imagination in London's work, the use of imagination in both his fiction and nonfiction, and the ways he defined imagination in the creative process in his business dealings with his publishers, editors, and agents. In this first volume of a two-volume biography, Williams traverses the years 1893 to 1902, from London's "Story of a Typhoon" to The People of the Abyss. The Jack London who emerges in the pages of Author Under Sail is a writer whose partnership with publishers, most notably his productive alliance with George Brett of Macmillan, was one of the most formative in American literary history. London pioneered many author models during the heyday of realism and naturalism, blurring the boundaries of these popular genres by focusing on absorption and theatricality and the representation of the seen and unseen. London created an impassioned, sincere, and extremely personal realism unlike that of other American writers of the time. Author Under Sail is a literary tour de force that reveals the full range of London as writer, creative citizen, and entrepreneur at the same time it sheds light on the maverick side of machine-age literature.Description based on publisher supplied metadata and other sources.Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, YYYY. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries
- …
